Insider buying last 90 days
No open-market insider purchases were filed for AMLX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every AMLX insider filing, plotted on the chart in Gekko.Open AMLX in Gekko
NASDAQ: AMLX
Amylyx Pharmaceuticals (AMLX) Stock Analysis & Forecast
Oct 12 close
$27.48−0.66 (−2.3%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on Amylyx Pharmaceuticals' Phase 3 LUCIDITY trial for avexitide, targeting post-bariatric hypoglycemia, a condition with no FDA-approved therapies. Topline data was presented at the ObesityWeek 2026 Annual Meeting, drawing positive coverage. Mizuho raised its price target to $24 while maintaining an Outperform rating. Separately, the company reported Q2FY26 results showing $250.8 million in cash and marketable securities, with operating expenses rising 7% to $45.7 million amid commercial readiness spending for avexitide. A director also proposed selling 100,000 shares, alongside a related Form 144 filing.
AMLX closed at $27.48, down 2.3%, sitting between its 50-day average of $30.29 and 200-day average of $18.98, with 1-month performance at -13.1% against a 1-year return of 89.9%. The GekkoIndex reads 66, placing the stock in the Accumulation zone. The current price sits 14.9% below the Gekko Fair Value of $32.29.
Looking ahead, Amylyx reports earnings on 5 November 2026, before the open, falling within the next 20 trading days and historically producing an average absolute reaction of 6.6%. Seasonality over the past 4 years shows a 16.4% average move across the next 20 trading days, though gains occurred in only 1 of those years. Analyst consensus stands at 9 buy ratings with a consensus target of $42.36, implying 54.1% upside.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Amylyx Pharmaceuticals price vs fair value
Close $27.48200-day averageGekko Fair Value $32.29
Amylyx Pharmaceuticals quick facts
- Market cap
- $3.06B
- P/E ratio
- —
- Forward P/E
- 2.8
- EPS, TTM
- −$1.41
- Revenue, TTM
- −$665K
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- -0.09
- Volume
- 1.11M avg 1.43M
- 1-year return
- +89.9%
- Typical daily move
- ±5%
- Typical 20-day move
- ±14.2%
- 50-day average
- $30.29
- 200-day average
- $18.98
- Next earnings
- Nov 5 before open
- Shares outstanding
- 125.5M
Amylyx Pharmaceuticals swing-trade checklist
Amylyx Pharmaceuticals scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $27.48 sits between the 50-day ($30.29) and 200-day ($18.98) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
66, Accumulation
Reading 66 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
14.9% below
Price is 14.9% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 24 days
Reports on Nov 5, 2026, 24 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitymixed
+16.4% on average
From this point in the calendar, the next 20 trading days averaged +16.4% over 4 years, rising in 1 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Amylyx Pharmaceuticals stock chart and price history
Amylyx Pharmaceuticals closed at $27.48 on Oct 12, 2026, +89.9% over the past year, inside a 52-week range of $10.83 to $41.14.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −13.1%
- 3 months
- +51.0%
- 6 months
- +66.8%
- 1 year
- +89.9%
The full AMLX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open AMLX in Gekko
Follow Amylyx Pharmaceuticals through every session
Put AMLX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track AMLX in GekkoFree for 7 days. No credit card required.
About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals works on developing drug treatments for amyotrophic lateral sclerosis and other conditions that cause nerve cells to break down over time. It has not yet brought products through to full commercial approval, placing it among firms still proving out their science rather than selling finished medicines at scale. The company is perhaps most associated with AMX0035, an experimental compound designed to block two separate pathways, unfolded protein response and Bax-driven cell death, that are believed to contribute to the loss of nerve cells in ALS.
AMX0035 combines sodium phenylbutyrate with taurursodiol and is being studied both as a potential ALS therapy and for possible use in other neurodegenerative diseases. The company's work centers on this research and development pipeline rather than on an established commercial product line.
Amylyx Pharmaceuticals was founded in 2013 and operates out of Cambridge, Massachusetts. Its shares trade on the NASDAQ under the ticker AMLX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- amylyx.com
Amylyx Pharmaceuticals GekkoIndex: the smart money zone
Amylyx Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 66, in the Accumulation zone, down 0.2 points over five sessions.
66Accumulation
Down 0.2 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 42 | 0.0% | +0.1% | ||
| Accumulation (current zone) | 184 | +1.4% | +3.9% | ||
| Neutral | 362 | +3.2% | +12.3% | ||
| Distribution | 93 | −2.1% | +2.0% | ||
| Selling | 1 | Too few readings yet | |||
Average AMLX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.2% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the AMLX price, zone by zone.Track AMLX in Gekko
Is Amylyx Pharmaceuticals stock overvalued? Gekko Fair Value
Amylyx Pharmaceuticals trades 14.9% below Gekko Fair Value of $32.29, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Amylyx Pharmaceuticals shares are worth, recalculated every trading day.
$32.29
Gekko Fair Value, Oct 10, 2026
14.9% Undervalued
At the end of Aug 2026 the price was 5.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open AMLX in Gekko
Amylyx Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Amylyx Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in AMLX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for AMLX, plotted on the chart in Gekko.Open AMLX in Gekko
Buybacks
Amylyx Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2025
- $885K
- As a share of market cap
- 0.03%
From company filings.
Amylyx Pharmaceuticals earnings: next date and track record
Amylyx Pharmaceuticals reports on Nov 5, 2026, before the open (24 days away), and beat the EPS estimate in 3 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected before the open, 24 days away
- EPS estimate
- −$0.38
- Revenue estimate
- $59K
3 of 8reports beat the EPS estimate
±6.6%average move across the report
3 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 6, 2026 AI summary
- What they said
- Amylyx is approaching a pivotal Phase III LUCIDITY trial top-line data readout for avexitide (GLP-1 receptor antagonist) in post-bariatric hypoglycemia (PBH), expected late August or early September 2026. The last participant completed their final visit and the database remains blinded. The company is simultaneously advancing NDA readiness and building commercial infrastructure including field medical affairs, marketing, and market access teams. Disease state education campaigns were activated at ENDO 2026.
- Guidance
- Management targets potential avexitide commercialization in 2027 if approved, contingent on positive LUCIDITY data and NDA submission. No specific revenue or earnings targets were provided. Top-line data expected late August or early September 2026.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$0.39 est −$0.36 | — | +4.4% |
| May 7, 2026 | −$0.37 est −$0.34 | — est −$52K | −8.3% |
| Mar 3, 2026 | −$0.30 est −$0.34 | — est −$52K | −1.6% |
| Nov 6, 2025 | −$0.37 est −$0.43 | — est $52K | −7.0% |
| Aug 7, 2025 | −$0.46 est −$0.44 | — | −6.7% |
| May 8, 2025 | −$0.42 est −$0.45 | — | −5.3% |
| Mar 4, 2025 | −$0.55 est −$0.49 | $665K | +12.0% |
| Nov 7, 2024 | −$0.53 est −$0.47 | $416K | +7.7% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Amylyx Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Amylyx Pharmaceuticals is $42.36, +54.1% from the last close, from 9 firms rating the stock in the last 90 days.
$42.36consensus 12-month target, +54.1% from the last close
Now $27.48Avg $42.36
Low $32High $57
Each firm’s latest rating in the last 90 days: 9 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | Stifel Nicolaus | $45 | +63.8% |
| Aug 26 | Guggenheim | $57 | +107.4% |
| Aug 22 | LifeSci Capital | $44 | +60.1% |
| Aug 20 | H.C. Wainwright | $55 | +100.1% |
| Aug 19 | Citi | $32 | +16.4% |
+3.9%average 20-day move after past Accumulation readings
+16.4%average move over the next 20 trading days in the last 4 years
±5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Amylyx Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Amylyx Pharmaceuticals averaged +16.4% across the last 4 years, rising in 1 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.0% | 3 of 4 |
| Next 10 trading days | +11.8% | 2 of 4 |
| Next 15 trading days | +11.8% | 2 of 4 |
| Next 20 trading days | +16.4% | 1 of 4 |
| Next 30 trading days | +7.0% | 3 of 4 |
For scale, AMLX’s typical 20-trading-day move in either direction is about 14.2%.
Amylyx Pharmaceuticals market cap and key statistics
Amylyx Pharmaceuticals’s market cap is $3.06B and revenue of −$665K over the last twelve months.
Valuation
- Market cap
- $3.06B
- Forward P/E
- 2.8
- EPS, TTM
- −$1.41
- Gekko Fair Value
- $32.29
Trading
- Volume
- 1.11M
- Avg volume, 20 days
- 1.43M
- 52-week high
- $41.14
- 52-week low
- $10.83
- Shares outstanding
- 125.5M
Financials
- Revenue, TTM
- −$665K
- Profit margin
- 0%
- Return on equity
- -74.7%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- -0.09
- Typical daily move
- ±5%
- Typical 20-day move
- ±14.2%
Amylyx Pharmaceuticals stock news this week
Coverage of Amylyx Pharmaceuticals this week reads positive: 6 positive, 2 neutral and 2 negative headlines.
- Amylyx Pharmaceuticals (AMLX) Could Be 35% Undervalued On Phase 3 LUCIDITY Data RevealSimply Wall Street, Oct 9
- Under a preset trading plan, Amylyx Pharmaceuticals (AMLX) director sells 30,000 shares.Stock Titan, Oct 8
- Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual MeetingBioSpace, Oct 7
- What Amylyx Pharmaceuticals (AMLX)'s Phase 3 Data Presentation Means For ShareholdersSimply Wall Street, Oct 7
- Mizuho raises Amylyx price target to $24, maintains Outperformscanx.trade, Oct 6
- A director proposes selling 100,000 shares of Amylyx Pharmaceuticals (AMLX).Stock Titan, Oct 6
Amylyx Pharmaceuticals peers
Amylyx Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 14.7% above |
| JNJJohnson & Johnson | Neutral | 3.2% below |
| ABBVAbbVie | Distribution | 28.2% above |
| MRKMerck | Neutral | 8.0% below |
| AZNAstraZeneca | Accumulation | 41.7% below |
| PFEPfizer | Neutral | 8.0% below |
A peer links to its own page where one exists.
Amylyx Pharmaceuticals stock FAQ
What is Amylyx Pharmaceuticals’s market cap?
Amylyx Pharmaceuticals’s market cap is $3.06B at the Oct 12, 2026 close of $27.48, with 125.5M shares outstanding.
What is the Amylyx Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Amylyx Pharmaceuticals is $42.36, +54.1% from the last close. Of the 9 firms that rated the stock in the last 90 days, 9 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Amylyx Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Amylyx Pharmaceuticals is undervalued: the Oct 12, 2026 close of $27.48 is 14.9% below Gekko Fair Value of $32.29. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Amylyx Pharmaceuticals report earnings next?
Amylyx Pharmaceuticals is expected to report on Nov 5, 2026, before the market opens (24 days away). Analysts expect earnings of −$0.38 per share on revenue of $59K. Amylyx Pharmaceuticals beat the earnings estimate in 3 of its last 8 reports, moving 6.6% on average across the report.
What is Amylyx Pharmaceuticals’s 52-week high and low?
Amylyx Pharmaceuticals’s 52-week high is $41.14 and its 52-week low is $10.83; it closed at $27.48 on Oct 12, 2026, +89.9% over the past year. Over the last five years the shares peaked at $41.93 on Jan 30, 2023.
Is Amylyx Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (gekkoindex and fair value), 2 as mixed (trend and seasonality) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Amylyx Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.